Literature DB >> 6238085

FcR epsilon+ lymphocytes and regulation of the IgE antibody system. II. FcR epsilon+ B lymphocytes initiate a cascade of cellular and molecular interactions that control FcR epsilon expression and IgE production.

J F Marcelletti, D H Katz.   

Abstract

This study additionally explores the orderly sequence of events concerning the induction of Fc receptors for IgE (FcR epsilon) that are initiated by IgE and mediated by IgE-induced regulants (EIR). Thus, lymphoid cells exposed to monomeric IgE displayed an early phase of exclusive B cell FcR epsilon expression, followed by the progressive appearance of FcR epsilon+ T cells, ultimately resulting in equal proportions of FcR epsilon+ B cells and T cells. Parallel cultures of lymphoid cells stimulated with EIR derived from unfractionated lymphoid cells (EIRT) also manifested rapid induction of FcR epsilon+ cells, but these FcR epsilon+ cells were predominantly T cells from the outset. Data presented here demonstrate that IgE-induced FcR epsilon expression by B cells ultimately results in the production of EIRT, which then induces FcR epsilon expression by T cells. The existence of EIRT that selectively induce T cell FcR epsilon expression prompted us to search for an EIRB that is selectively active in inducing FcR epsilon+ B cells. Indeed, IgE-stimulated, T cell-depleted lymphoid cells produce an EIRB that selectively induces FcR epsilon expression by B cells. This EIRB, but not EIRT, can also be generated by IgE stimulation of Lyt-2+ cell-blocked lymphoid cells, indicating that Lyt-1+ cells are not inhibitory to EIRB production and that production of EIRT is dependent upon functionally competent Lyt-2+ cells. Similar to IgE, EIRB induces rapid FcR epsilon expression, first by B cells and then by T cells, so that by 16 hr post induction equal proportions of FcR epsilon+ B and T cells were observed. Although complete T cell depletion does not affect IgE-induced FcR epsilon expression, selective blocking of Lyt-1+ cells markedly diminishes such responses, suggesting that Lyt-2+ cells are antagonistic to the induction of FcR epsilon+ B cells. Studies involving sequential T cell subset depletion clearly demonstrated that in the absence of functionally competent Lyt-1+ cells, Lyt-2+ cells exert an inhibitory influence on IgE-induced FcR epsilon expression by B cells. Stimulation of Lyt-1+ cell-blocked cultures with EIRT, and to a lesser degree with IgE, resulted in the elaboration of an EIR (EIRI), which lacks direct FcR epsilon-inductive properties, but conversely, directly inhibits IgE-induced FcR epsilon expression in fresh B cell cultures.

Mesh:

Substances:

Year:  1984        PMID: 6238085

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrates isotype regulatory function.

Authors:  H Kimata; A Saxon
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

2.  Induction of Fc epsilon receptors on normal murine T cells and IgE binding factor(s) by cross-linked IgE or IgE-pulsed adherent cells.

Authors:  M A Firer; Z Eshhar
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

3.  Regulation of IgE receptor expression on human peripheral blood lymphocytes by lymphocytosis promoting factor (LPF), lectins and dexamethasone.

Authors:  K M Kim; M Tanaka; T Yoshimura; K Katamura; M Mayumi; H Mikawa
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

4.  Studies on in vitro IgE synthesis from lymph node cells of mice during infection with Nippostrongylus brasiliensis. Presence of inhibitory factor(s) in serum.

Authors:  P Pfeiffer; I Rauschen; W König
Journal:  Parasitol Res       Date:  1987       Impact factor: 2.289

5.  IgE-antigen complexes enhance Fc epsilon R and Ia expression by murine B lymphocytes.

Authors:  M L Richards; J F Marcelletti; D H Katz
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.